Randomized phase II trial of parsatuzumab (anti-EGFL7) or placebo in combination with carboplatin, paclitaxel, and bevacizumab for first-line nonsquamous non-small cell lung cancer
The Oncologist Feb 15, 2018
von Pawel J, et al. - In this phase II trial, the addition of parsatuzumab, an anti-epidermal growth factor-like domain 7 (EGFL7) antibody, to the combination of bevacizumab and chemotherapy was not shown to be efficacious as first-line treatment for non-squamous non-small cell lung cancer (NS-NSCLC).
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
